Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Evoke Pharma (EVOK) Return on Equity (2020 - 2025)

Historic Return on Equity for Evoke Pharma (EVOK) over the last 6 years, with Q3 2025 value amounting to 1.35%.

  • Evoke Pharma's Return on Equity rose 3900.0% to 1.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.35%, marking a year-over-year increase of 3900.0%. This contributed to the annual value of 2.4% for FY2024, which is 79500.0% up from last year.
  • Per Evoke Pharma's latest filing, its Return on Equity stood at 1.35% for Q3 2025, which was up 3900.0% from 1.05% recorded in Q2 2025.
  • Evoke Pharma's 5-year Return on Equity high stood at 45.37% for Q3 2023, and its period low was 15.54% during Q1 2024.
  • Over the past 5 years, Evoke Pharma's median Return on Equity value was 1.72% (recorded in 2021), while the average stood at 0.07%.
  • As far as peak fluctuations go, Evoke Pharma's Return on Equity skyrocketed by 466400bps in 2023, and later crashed by -471100bps in 2024.
  • Evoke Pharma's Return on Equity (Quarter) stood at 2.08% in 2021, then increased by 18bps to 1.71% in 2022, then soared by 364bps to 4.51% in 2023, then plummeted by -121bps to 0.94% in 2024, then plummeted by -44bps to 1.35% in 2025.
  • Its last three reported values are 1.35% in Q3 2025, 1.05% for Q2 2025, and 0.79% during Q1 2025.